Objective. To investigate whether abnormalities in B cell subsets in patients with juvenile idiopathic arthritis (JIA) correlate with clinical features and response to treatment.
Methods. A total of 109 patients diagnosed as having oligoarticular JIA or polyarticular JIA were enrolled in the study. B cell subsets in peripheral blood and synovial fluid were analyzed by flow cytometry.
Results. Switched memory B cells were significantly increased in patients compared to age-matched healthy controls (P < 0.0001). When patients were divided according to age at onset of JIA, in patients with earlyonset disease (presenting before age 6 years) the expansion in switched memory B cells was more pronounced than that in patients with late-onset disease and persisted throughout the disease course. In longitudinal studies, during methotrexate (MTX) treatment, regardless of the presence or absence of active disease, the number of switched memory B cells increased significantly (median change from baseline 36% [interquartile range {IQR} 15, 66] ). During treatment with MTX plus tumor necrosis factor inhibitors (TNFi), in patients maintaining disease remission, the increase in switched memory B cells was significantly lower than that in patients who experienced active disease (median change from baseline 4% [IQR À6, 32] versus 41% [IQR 11, 73] ; P = 0.004). The yearly rate of increases in switched memory B cells was 1.5% in healthy controls, 1.2% in patients who maintained remission during treatment with MTX plus TNFi, 4.7% in patients who experienced active disease during treatment with MTX plus TNFi, and~4% in patients treated with MTX alone.
Conclusion. Switched memory B cells expand during the disease course at a faster rate in JIA patients than in healthy children. This increase is more evident in patients with early-onset JIA. TNFi treatment inhibits this increase in patients who achieve and maintain remission, but not in those with active disease.
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children. The 2001 update of the International League of Associations for Rheumatology (ILAR) criteria for JIA identifies 8 different categories based on the number of joints involved, laboratory findings, and extraarticular manifestations (1) . The goal of this classification is to group JIA patients into relatively homogeneous categories; however, it is still debated whether these categories group together patients with diseases having common pathogenic mechanisms. In fact, several problems with the present classification are emerging (2, 3) . For example, it has been proposed that early-onset JIA (presenting before age 6 years) is a distinct clinical entity, regardless of the number of joints involved. Indeed, genetic studies of associations with HLA alleles (4), immunologic studies involving B lymphocytes (5) , and the presence of specific clinical features (6) support this proposal.
Methotrexate (MTX) is used as first-line treatment in patients with JIA, and tumor necrosis factor inhibitors (TNFi) have been shown to be effective in patients with an unsatisfactory response to MTX. Some studies have investigated alterations in circulating B cell subsets in JIA patients, but no major abnormalities have been found (7, 8) . Given the well-known role of TNF in B cell development and germinal center (GC) reactions and the possible relationship between these effects and therapeutic efficacy (9,10), our aim was to study the distribution of B cell subsets in the peripheral blood of a large cohort of patients with JIA and the correlation of these subsets with disease activity and response to MTX and TNFi.
PATIENTS AND METHODS
Patients and study design. We enrolled 109 patients diagnosed as having oligoarticular JIA or polyarticular JIA according to the ILAR criteria (1). The characteristics of the patients are shown in Table 1 . For each patient, we recorded clinical data and laboratory parameters. Antinuclear antibody (ANA) positivity was defined as the presence of a high titer of ANAs (≥1:160) on at least 2 occasions, 3 months apart. Approximately 66% of patients with oligoarticular JIA or polyarticular JIA were ANA positive. Age-matched children were used as healthy controls (n = 304).
Of these 109 patients, 50 patients receiving either MTX alone (n = 17) or MTX plus TNFi (n = 33) were followed up for a median of 11.2 months (range 6.9-21.2 months); their B cell subsets were measured at the first (time 0) and last (time 1) followup visits. Active disease was defined as the presence of tender or swollen joints, a high erythrocyte sedimentation rate and/or C-reactive protein (CRP) level, and/or active uveitis. Remission was defined according to the criteria described by Wallace et al (11) .
B cell phenotyping. Peripheral blood mononuclear cells from 109 patients and 304 healthy controls or synovial fluid mononuclear cells (SFMCs) from 18 patients were isolated by Ficoll density-gradient centrifugation and frozen. Mononuclear cells were thawed, counted, assessed for viability, and stained with the following antibodies: phycoerythrin (PE)-Cy5-conjugated anti-CD19 (HIB19), PE-Cy7-conjugated anti-CD38 (HB7), PE- SFMC culture conditions and ANA assay. In order to have a sufficient number of SF B cells for cell culture, CD19+ cells from 13 JIA patients (~85% with oligoarticular JIA) were sorted and cultured together with non-B cells as the feeder layer and stimulated with CpG, as previously described (12) . After 8 days of culture, supernatants were collected, and cells were stained to analyze the expression of surface markers. The concentration of total IgG in supernatants was assessed with an inhouse enzyme-linked immunosorbent assay (12) . The presence of ANAs secreted by memory B cells in undiluted or diluted supernatants was assayed by a commercial ANA kit (ANA Hep2; Eurospital) and detected with FITC-conjugated anti-human IgG. Samples with the highest concentration of IgG were diluted in order to adjust for differences in the amount of total IgG produced in vitro; ANA reactivity remained positive with a concordant nuclear pattern in diluted samples.
Statistical analysis. A nonparametric t-test or analysis of variance (ANOVA) followed by Bonferroni post hoc test was used to analyze data. P values less than 0.05 were considered significant.
RESULTS
Increased switched memory B cells in patients with oligoarticular JIA or polyarticular JIA. The relative frequency and absolute number of CD19+ B cells were significantly increased in JIA patients in comparison to age-matched healthy controls ( Figure 1A ; also see Supplementary Table 1 , http://onlinelibrary.wiley.com/doi/10. 1002/art.40410/abstract). The percentages of transitional and naive B cells did not differ between JIA patients and healthy controls ( Figure 1A ). We found a significant difference in the B cell memory pool. Switched memory B cells were significantly increased in JIA patients, while IgM memory B cells were significantly reduced (Figure 1A) . When we calculated the absolute numbers, we * Except where indicated otherwise, values are the number (%). JIA = juvenile idiopathic arthritis; ANA = antinuclear antibody; IQR = interquartile range; NSAIDs = nonsteroidal antiinflammatory drugs; MTX = methotrexate; TNFi = tumor necrosis factor inhibitors.
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found that all B cell populations were increased in JIA patients (as expected based on the expansion of total CD19+ cells that we and other investigators observed [13] ) except for transitional B cells, numbers of which were within the normal range (Supplementary Table 1 ). The frequency of IgM memory and switched memory B cells increases throughout childhood upon encounters with antigens (12) . However, the absolute number of circulating memory B cells decreases over time due to the reduction in the total number of circulating B cells observed after age 4 years (14, 15) . In order to study the dynamic changes of the memory B cell compartment in children, we determined the relative frequency of IgM memory and switched memory B cells as a function of Switched memory B cells were expanded in JIA patients until age 16 years, while no statistically significant differences were observed between adult JIA patients and adult healthy controls (Supplementary Figure 2) . IgM memory B cells appeared to be significantly reduced only in very young children with JIA ( Figure 1B ; also see Supplementary Figure 2) . In expression profile studies, Barnes et al (5) observed that a B cell signature characterizes patients with oligoarticular JIA or polyarticular JIA with disease beginning before age 6 years (referred to as early-onset JIA) and distinguishes patients with early-onset JIA from those with late-onset JIA and systemic-onset JIA. We divided our JIA patients according to age at the time of disease onset and, to correct for age-related differences in memory B cells, took into account the age at which the blood sample was drawn. In patients with early-onset disease and age <6 years at sampling, switched memory B cells were expanded and IgM memory B cells were reduced compared to age-matched healthy controls (Figures 2A and B) . In patients age >6 years at the time of sampling with either early-onset JIA (age <6 years) or late-onset JIA (age >6 years), the frequency of switched memory B cells was significantly increased compared to the frequency in age-matched healthy controls, while the frequency of IgM memory B cells was comparable to that in age-matched healthy controls (Figures 2A and B) . Of note, among patients in whom blood samples were obtained at age >6 years, the frequency of switched memory B cells was higher in those with onset at age <6 years than in those with onset at age >6 years. These results are consistent with the conclusion that switched memory B cells are significantly expanded in JIA patients, and that this expansion is more pronounced in patients with earlyonset JIA and persists throughout the disease course.
Switched memory B cells are present in inflamed joints and are a source of ANAs. The target organ in JIA is the synovium. Therefore, we sought to analyze the B cell subsets found in SF obtained from JIA patients. As described in a previous report (7) , the total number of B cells was lower than that in peripheral blood, accounting for 1% of SFMCs. Of note, >60% of these B cells were switched memory B cells ( Figure 3A) , consistent with previous observations (7, 17) .
Memory B cells are the main B cells responding to CpG (a Toll-like receptor 9 agonist) by proliferating and differentiating into immunoglobulin-secreting plasmablasts (18) . After stimulation with CpG, SF memory B cells from 13 JIA patients expanded, acquired a plasmablast phenotype (CD19 low CD27++CD38++), and secreted IgG in the supernatants ( Figure 3B ). We previously showed that after stimulation with CpG, switched memory B cells are responsible for almost all of the IgG secreted in culture (12) . Therefore, we tested whether the IgG produced by switched memory B cells in the supernatants contained ANAs. In 6 of 7 ANA-positive patients, IgG secreted by SF switched memory B cells contained ANAs; in contrast, ANAs were undetectable in 6 ANA-negative patients (P = 0.0047 by Fisher's exact test) ( Figure 3C ). We also tested the reactivity of supernatants of unstimulated culture of SFMCs, and no ANAs were detected (data not shown), indicating that there was no basal production of ANAs and that these autoantibodies were secreted by memory B cells only after stimulation with CpG. Taken together, these data show that switched memory B cells are Figures 3B-F Figure 3D , http://onlinelib rary.wiley.com/doi/10.1002/art.40410/abstract). These data are in apparent contrast to a previous report (10) that in adults with rheumatoid arthritis (RA), TNFi caused a reduction in GCs and in circulating memory B cells. Since duration of treatment may be an important variable to consider, we assessed changes in switched memory B cells during treatment with MTX alone and during treatment with MTX plus TNFi.
In patients treated with MTX alone, there was a progressive increase in switched memory B cells over time, and this correlated significantly with treatment duration (r = 0.39, P = 0.03) (Figure 4 ). This increase is consistent with previous observations in MTX-treated patients with RA (10) and in MTX-treated patients with JIA (19) as well as with the known increase in switched memory B cells with age in children (12) . In contrast, in patients treated with MTX plus TNFi, the percentage of switched memory B cells did not change (Figure 4 ). Since MTX is known to have no effect on the development of switched memory B cells (19) , their increase in patients treated with MTX alone may simply reflect a physiologic increase with age. The absence of a physiologic increase in switched memory B cells in patients treated with MTX plus TNFi can be explained by the above-mentioned inhibitory effect of TNFi on GCs and on generation and maintenance of switched memory B cells.
TNFi reduce the rate of increase in switched memory B cells only in patients who achieve disease remission. To confirm the effect of TNFi on switched memory B cells mentioned above, we analyzed changes in the percentage of switched memory B cells over time and correlated them with the therapeutic response to TNFi. Fifty JIA patients were followed up during treatment with either MTX alone (n = 17) or MTX plus TNFi (n = 33) for~1 year. Figure 5A shows the percentage of switched memory B cells at the first (time 0) and second (time 1) sampling (median interval 11.2 months). As expected based on the known increase with age and the data shown previously, in patients treated with MTX alone the percentage of switched memory B cells increased significantly during the follow-up period (median increase from baseline 36% [IQR 15, 66] ). There were no differences between patients who achieved and maintained remission during treatment with MTX alone (31% increase from baseline [IQR 9, 57]) and those who did not (47% increase from baseline [IQR 6, 73]) (P = 0.5). For this reason, and to simplify the analysis, we included both groups of patients in a single MTX treatment group. In patients treated with MTX plus TNFi who experienced active arthritis or uveitis during treatment (group A), switched memory B cells increased significantly (median increase of 41% from baseline [IQR 11, 73] ) to an extent comparable to that in patients treated with MTX alone. In contrast, in patients treated with MTX plus TNFi who achieved and maintained remission during the follow-up period (group R), switched memory B cells did not increase significantly (median increase of 4% from baseline [IQR À6, 32]) ( Figures 5A and B) .
To correct for variability in the duration of followup, we calculated, for each patient, the yearly rate at which switched memory B cells increased over time, determining the slope of the line passing through the 2 points. The slope of the line for MTX plus TNFi-treated patients who experienced active arthritis or uveitis was significantly higher than the slope of the line for MTX plus TNFitreated patients who achieved and maintained remission Figure 5C ). Knowing the average slope for the different groups of patients, we modeled the equation defining the rate at which switched memory B cells increased over time. It is evident that during a period of 12 months, switched memory B cells increased by~4% per year in patients receiving MTX alone and 4.7% per year in patients receiving MTX plus TNFi who experienced active arthritis or uveitis (group A). On the other hand, in patients receiving MTX plus TNFi who achieved and maintained remission (group R), the rate was significantly lower (1.2% per year) and comparable to the increase calculated in our cohort of healthy children (1.5% per year) ( Figure 5D ).
DISCUSSION
We showed that the numbers of circulating switched memory B cells were increased in patients with oligoarticular JIA and patients with polyarticular JIA, especially in those with disease onset before age 6 years. We also showed that switched memory B cells were the most represented B cell subset in SF, and that SF switched memory B cells produced ANAs. Importantly, we found that changes in the frequency of peripheral blood switched memory B cells were associated with a therapeutic response to TNFi.
Previous studies have analyzed B cell subsets in the blood of JIA patients. In one study, switched memory B cells were found to accumulate in the SF of JIA patients; however, the numbers of switched memory B cells in the blood of JIA patients were found not to be different from the numbers in blood from healthy controls (7) . The apparent discrepancy with our findings might be explained by differences in disease severity (only 1 patient was receiving TNFi [7] ) and by differences in the controls. That study had a small group of controls (n = 20) with a mean age comparable to that of patients. However, no Figure 5 . A, Percentage of switched memory B cells at baseline (T0) and after 12 months (T1) in patients treated with methotrexate (MTX) alone (n = 17) or with MTX plus tumor necrosis factor inhibitors (TNFi) (n = 33). Those treated with MTX plus TNFi were divided into those who achieved and maintained remission (group R) (n = 14) and those who experienced disease flares (group A) (n = 19). B, Percentage increase from baseline (dashed line) of switched memory B cells in the 3 groups of patients described in A. C, Slopes expressing the steepness of the line conjoining the percentages of switched memory B cells at baseline (dashed line) and at the second blood drawing. D, Illustration of the rate at which switched memory B cells increased over time. Using the average slope for patients treated with MTX alone, those treated with MTX plus TNFi who achieved remission, and those treated with MTX plus TNFi who had disease flares, we modeled the functions expressing the yearly increase in switched memory B cells in the 3 groups of patients. In B and C, symbols represent individual subjects; solid horizontal lines indicate the median. NS = not significant; HC = healthy controls.
information was provided about the distribution of B cell subsets across the different ages, and patients and controls of different ages were not compared. More recently, a study of B cell subsets in JIA patients (19) demonstrated that different treatments, including TNFi, did not directly affect circulating memory B cells. That study did not include a longitudinal evaluation; moreover, a comparison with our data is not possible because various subsets of patients with JIA were included, and no comparison with age-matched healthy controls was available.
In our study we evaluated a large number of patients; we focused on 2 relatively homogeneous subsets of patients with JIA, excluding those with rheumatoid factor, enthesitis-related arthritis, psoriatic arthritis, or systemic-onset arthritis. We also used as a control group a large series of healthy children across all ages. The expansion of switched memory B cells was associated with age at onset, being significantly more pronounced in patients with early-onset JIA (presenting before age 6 years). Interestingly, age at onset has been reported to distinguish patients with different pathophysiologic mechanisms (5) . A study of HLA association in JIA showed that HLA-DR5 increases the risk of developing JIA early in life (ages 0-8 years) but not at later ages (4) . A B cell signature has been shown to characterize patients with disease onset before age 6 years (5); interestingly, this B cell signature was able to distinguish patients with early-onset JIA from those with late-onset JIA, regardless of the number of affected joints at presentation, and from patients with systemic-onset JIA.
We speculate that 2 main mechanisms, not necessarily mutually exclusive, may explain the expansion of switched memory B cells in JIA. First, B cells from patients with JIA may bear an intrinsic lower threshold for activation, as reported for other autoimmune diseases (20) , favoring IgG switching and differentiation into memory B cells. Second, since switched memory B cells develop in GCs, the expansion of switched memory B cells may be the consequence of enhanced GC formation. Two pieces of evidence support the latter hypothesis. A genome-wide association study found that a coding singlenucleotide polymorphism in the lymphotoxin b receptor gene was associated with the development of oligoarticular JIA and polyarticular JIA (21) . Indeed, the lymphotoxin axis plays a crucial role in GC development (22) . Moreover, in the synovial membrane of patients with oligoarticular JIA or polyarticular JIA, the presence of organized B and T cell follicles and the presence of GCs within these structures correlated with the presence of ANAs (23) .
As mentioned previously, switched memory B cells are the main subset of B cells found in SF from patients with oligoarticular JIA and those with polyarticular JIA. Our finding that switched memory B cells from SF produce ANAs suggests a direct link between this cell subset and the typical autoimmune feature of the disease. Further pointing to their potential pathogenic role, switched memory B cells in SF from JIA patients were shown to be efficient antigen-presenting cells and to favor Th1 polarization of Tcells (17) .
We did not find any association between circulating levels of switched memory B cells and disease activity, as measured by the number of joints with active disease and CRP levels (see Supplementary Figure 3 , http:// onlinelibrary.wiley.com/doi/10.1002/art.40410/abstract). Circulating memory B cells reflect the overall immune responses of the host; for example, switched memory B cells significantly and quickly expand in response to the environmental pathogen milieu, with vaccination being a well-known example (24) . These responses may dilute the contribution of switched memory B cells leaking from the inflamed joints, making it difficult to observe a direct correlation with disease activity or other features of JIA. Another factor that may influence the frequency of switched memory B cells is disease duration, especially in children with early-onset JIA; in patients with longer disease duration, switched memory B cells may accumulate due to the ongoing autoimmune response. However, no significant correlation was observed between frequency of switched memory B cells and disease duration, even when the patients were grouped according to age at disease onset and age at sampling as discussed above (data not shown). Finally, assessing disease activity only through CRP levels and number of joints involved may not be ideal, especially in patients with oligoarticular JIA, who represent a significant proportion of patients in our cohort. Longitudinal studies closely assessing disease activity, disease damage, and long-term outcomes will be needed to investigate whether these parameters correlate with switched memory B cells and their change over time.
The TNF pathway plays a pivotal role in GC development. As predicted from the results of animal studies (9) , in RA patients administration of TNFi led to disruption of GC structures in lymphoid tissues by affecting the supporting network of follicular dendritic cells, and, subsequently, to the reduction in the frequency of circulating memory B cells (10) . We report that treatment with TNFi affects the expansion of switched memory B cells in patients with JIA, as reflected by the reduction in the rate of accumulation in the periphery. In healthy children, switched memory B cells increase progressively during childhood (12) , and indeed we show that switched memory B cells increase constantly at a rate of~1.5-2% per year until age 18 years (Figures 1 and 5) . In JIA patients studied longitudinally, switched memory B cells increase in the periphery at a much faster rate than that in healthy control children. As predicted by the above-mentioned observations in animals and RA patients, treatment with TNFi affects the rate of switched memory B cell expansion. Interestingly, treatment with TNFi reduces the rate of switched memory B cell expansion to a level comparable to that in healthy controls only in patients achieving and maintaining remission during treatment. In sharp contrast, in patients who either did not achieve remission or had disease flares during treatment with TNFi, the yearly rate of switched memory B cell increase was much higher and comparable to that in patients receiving MTX alone.
The therapeutic benefit of TNFi in arthritis may be secondary to a number of mechanisms, including, for example, rapid effects on proinflammatory cytokine production, as anticipated by the original observation on synoviocytes (25) . Interestingly, several studies have shown that in RA patients, switched memory B cells are the target of many biologic drugs (TNFi, rituximab, tocilizumab, and abatacept), and a reduction in this subpopulation is associated with more favorable outcomes (10, (26) (27) (28) . Based on our results and on the above-mentioned observations in lymphoid tissues in humans, it is tempting to speculate that inhibition of GCs and of the generation of switched memory B cells may contribute to the ability of TNFi to induce and maintain disease remission in JIA. In TNFi-treated patients who do not achieve remission or have a disease flare, TNFi are not able to control the disease either because they cannot completely neutralize tissue TNF or because the GC reactions, and possibly the switched memory B cells themselves, do not play a crucial role in this subset of patients.
In conclusion, we show that switched memory B cells are expanded in JIA patients, particularly in those with early onset of disease, further pointing to a peculiar subset of JIA patients with early-onset disease. TNFi limit the expansion of switched memory B cells in patients who respond to treatment and achieve remission. Further studies are necessary to elucidate in greater detail the role of memory B cells in JIA pathogenesis and their correlation with the disease course, and to validate their usefulness as biomarkers of disease classification and response to treatment.
